Gemzar

The company markets two cancer medicines: Alimta, used to treat a form of lung cancer, and Gemzar, which is approved to treat several types, including lung, pancreatic, ovarian and metastatic breast cancer.

Lilly Is in Talks to Buy ImClone 2008

The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar, which is used in the treatment of ovarian, lung, breast and pancreatic cancer.

Domain-b Brand Dossier 2010

Global sales of Gemzar, which is already facing generic competition in many overseas markets, fell 17 percent to $293 million in the second quarter.

Yahoo! News: Business - Opinion 2010

Sales of cancer drug Gemzar dropped 22% due to generic competition.

Eli Lilly Profit Jumps 28% on Better Revenue, Margins Peter Loftus 2011

Co. patent for anti-cancer drug Gemzar is invalid, a decision that may clear the way for generic competition to the drug late this year.

Eli Lilly Loses Appeal in Gemzar Patent Case 2010

Gemzar sales for the first half of 2010 declined 19% to $581 million, because of lower selling prices in the U.S. and the availability of generics in foreign markets.

Eli Lilly Loses Appeal in Gemzar Patent Case 2010

Cancer drug Alimta rose 43%, while another cancer drug, Gemzar, declined 17%.

Earnings Watch 2010

The company said it expects to maintain market exclusivity for Gemzar until Nov. 15.

Eli Lilly Loses Appeal in Gemzar Patent Case 2010

Lilly also reported gains its cancer drug Alimta and Humalog insulin, while sales of cancer drug Gemzar declined.

Lilly Lowers Outlook Amid Health-Care Overhaul 2010

Lilly said in an April quarterly report that, if it lost the Gemzar appeal, a generic version of the drug could enter the U.S. market as early as November 2010.

Eli Lilly Loses Appeal in Gemzar Patent Case 2010